Biomarker Statistics - Summer 2026 Intern jobs in United States
info-icon
This job has closed.
company-logo

Sanofi · 1 day ago

Biomarker Statistics - Summer 2026 Intern

Sanofi is an innovative global healthcare company focused on improving people’s lives through science. They are seeking an intern to support statistical analysis of biomarker data and develop statistical methods for drug development and biomarker analysis.

Health CareLife SciencePharmaceuticalTherapeutics
badNo H1Bnote

Responsibilities

Support statistical analysis of biomarker data from clinical trials
Develop and implement statistical methods for multi-omics data integration
Assist in creating visualization tools for complex biological datasets
Collaborate with cross-functional teams on biomarker-driven projects

Qualification

RPythonStatistical methodsOmics data analysisMachine learningClinical trial designMolecular biologyCommunication skillsPresentation skills

Required

Currently enrolled and pursuing a PhD (3+ years) in Biostatistics, Statistics, Computer Science, Bioinformatics, Computational Biology or related field at an accredited college or university
Must be enrolled in school the semester following your internship/co-op with Sanofi
Experience with programming in R or Python
Knowledge of statistical methods and experimental design
Understanding of molecular biology concepts
Must be able to relocate to the office location and work 40hrs/week, Monday-Friday, for the full duration of the co-op/internship
Must be permanently authorized to work in the U.S. and not require sponsorship of an employment visa (e.g., H-1B or green card) at the time of application or in the future

Preferred

Experience with omics data analysis
Familiarity with machine learning approaches
Knowledge of clinical trial design
Strong communication and presentation abilities

Benefits

High-quality healthcare
Prevention and wellness programs
At least 14 weeks’ gender-neutral parental leave

Company

Sanofi is a global biopharma company focused on prescription drugs, vaccines, and treatments for chronic, rare, and infectious diseases.

Funding

Current Stage
Public Company
Total Funding
$6.97B
Key Investors
Blackstone Life SciencesEvotec
2025-10-28Post Ipo Debt· $3B
2025-06-17Post Ipo Debt· $1.74B
2025-03-05Post Ipo Debt· $1.59B

Leadership Team

leader-logo
Paul Hudson
Chief Executive Officer
linkedin
leader-logo
Francois-Xavier Roger
Chief Financial Officer
linkedin
Company data provided by crunchbase